Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (R01AI145971, P30AI027757)
National Institute of Mental Health (K23MH124466)
Received: 4 February 2022
Accepted: 9 June 2022
First Online: 16 June 2022
: Ethics approval was received from all pertinent approving bodies in Kenya and the USA: UW IRB STUDY00007487, KEMRI SERU P00122/3915, and PPB ECCT 19/11/02/2020(013). Written, informed consent to participate will be obtained from all participants.
: Not applicable—no identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. Informed consent materials are attached as supplementary materials.
: OOS has received research support (paid to the University of Washington) from Hologic Inc. and SpeeDX, outside of the submitted work. RSM has received fees for consulting from Lupin Pharmaceuticals and research funding (paid to the University of Washington) from Hologic Corporation, outside of the submitted work. RB reported receiving abstract and manuscript writing support from Regeneron Pharmaceuticals, outside the submitted work. JMB reported receiving personal fees from Gilead Sciences, Janssen, and Merck and is an employee of Gilead Sciences outside of the submitted work. No other disclosures were reported.